DOI QR코드

DOI QR Code

Clinical Comparison between Paclitaxel Liposome (Lipusu®) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer

  • Xu, Xu (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Wang, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Xu, Huan-Qin (Deaprtment of Internal Medicine, GaoGang People Hospital) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Qian, Ya-Dong (Deaprtment of Internal Medicine, GaoGang People Hospital) ;
  • Xiang, Jin (Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • 발행 : 2013.04.30

초록

Aim: To compare the efficacy and safety of paclitaxel liposome (Lipusu$^{(R)}$) with paclitaxel in combination with tegafur and oxaliplatin in treating patients with advanced gastric cancer. Materials and Methods: Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups. Patients in group A received paclitaxel liposomes at a dose of 135 $mg/m^2$ on day 1 of each cycle, and patients in group B were given paclitaxel at the same dose with the same timing. All patients received tegafur at a dose of 500 $mg/m^2$ on days 1-5, and oxaliplatin at a dose of 80-100 $mg/m^2$ on day 1 for 2 cycles (each cycle was 21 d in total). Results: Fifty-eight patients could be evaluated for efficacy. The overall response rate was 47% in group A (14/30), and 46% in group B (13/28). Disease control rate was 73% in group A (22/30), and 71% in group B (20/28) (P>0.05). No significant differences were detected in hematologic and neurologic toxicities between the two groups (P>0.05). However, nausea, vomiting and hypersensitive reactions were significantly lower in group A than in group B (P<0.05). Conclusion: Paclitaxel liposomes are as effective as paclitaxel when combined with tegafur and oxaliplation in treating patients with advanced gastric cancer, but adverse reactions with paclitaxel liposomes are less common.

참고문헌

  1. Belotti D, Vergani V, Drudis T, et al (1996). Themicrotubuleaffecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res, 2, 1843-9.
  2. Bookman MA, Kloth DD, Kover PE, et al (1997). Shortcourse intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol, 8, 611-4. https://doi.org/10.1023/A:1008207025430
  3. Chen Q, Zhang Q, Liu J, et al (2003). Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non small-cell lung cancer. Chin J Oncol, 25, 190-2.
  4. Drummond DC, Meyer O, Hong K, et al (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51, 691-743.
  5. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  6. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  7. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. https://doi.org/10.7314/APJCP.2012.13.5.1873
  8. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  10. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
  11. Kobayashi M, Tsuburaya A, Nagata N, et al (2006). A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer, 9,114-9. https://doi.org/10.1007/s10120-006-0364-9
  12. Kong Fh, Dong Qf, Cao X (2007). Effect of paclitaxel combined with cisplatin in treatment of non small cell lung cancer. Pract J Cancer, 22, 513-4.
  13. Kucukzeybek Y, Dirican A, Erten C, et al (2012). Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Asian Pac J Cancer Prev, 13, 2771-4. https://doi.org/10.7314/APJCP.2012.13.6.2771
  14. Li CG, Huang XE, Li Y (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  15. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  16. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  17. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  18. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  19. Luo J, Wu FY, Li AW, et al (2012). Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study. Asian Pac J Cancer Prev, 13, 4703-6. https://doi.org/10.7314/APJCP.2012.13.9.4703
  20. Scialli AR, Waterhouse TB, Desesso JM, et al (1997). Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology, 56, 305-10. https://doi.org/10.1002/(SICI)1096-9926(199711)56:5<305::AID-TERA3>3.0.CO;2-W
  21. Sharma A, Straubinger RM (1994). Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res, 11, 889-96. https://doi.org/10.1023/A:1018994111594
  22. Sharma D, Chelvi TP, Kaur J, et al (1996). Novel taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy. Oncol Res, 8, 281-6.
  23. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  24. Szebeni J, Muggia FM, Alving CR (1998). Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst, 90, 300-6. https://doi.org/10.1093/jnci/90.4.300
  25. Treat J, Damjanov N, Huang C, et al (2001). Liposomal encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology, 15, 44-8.
  26. Van Zuylen L, Karlsson MO, Verweij J, et al (2001). Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol, 47, 309-18. https://doi.org/10.1007/s002800000215
  27. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  28. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  29. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  30. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro Polymorphism and Bladder Cancer Risk-Meta-analysis Evidence for a Link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  31. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  32. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  33. Yang A, Li J, Xu H, et al (2006). A study on antitumor effect of liposome encapsulated paclitaxel in vivo and in vitro. Bull Chin Cancer, 15, 862-4.
  34. Yao CY, Huang XE, Tang JH, et al (2010). Clinical observationson safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev, 11, 553-5.
  35. Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  36. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  37. Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  38. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

피인용 문헌

  1. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  2. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  3. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  4. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  5. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  6. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  7. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  8. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  9. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  10. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  11. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  12. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  13. Further Study on Pemetrexed based chemotherapy in Treating Patients with Advanced Gastric Cancer (AGC) vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6587
  14. Isomeric Folate-Conjugated Polymeric Micelles Bind to Folate Receptors and Display Anticancer Effects vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7363
  15. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  16. Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
  17. Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10241
  18. Effect of Paclitaxel-loaded Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1725
  19. Systemic Analysis on Laparoscope-Assisted Gastrectomy for Patients with Gastric Cancer vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2027
  20. Peroxisome Proliferator-Activated Receptor-Gamma Pro12Ala Polymorphism Could be a Risk Factor for Gastric Cancer vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2333
  21. Sensitivity of Gastric Cancer Cells to Chemotherapy Drugs in Elderly Patients and Its Correlation with Cyclooxygenase-2 Expression vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3447
  22. Coenzyme Complex Decreased Cardiotoxicity When Combined with Chemotherapy in Treating Elderly Patients with Gastrointestinal Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4045
  23. Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals vol.41, pp.8, 2015, https://doi.org/10.3109/03639045.2014.950272
  24. Von der Zusammensetzung zur Heilung: ein systemtechnischer Ansatz zur Entwicklung von Trägern für Tumortherapeutika vol.129, pp.24, 2017, https://doi.org/10.1002/ange.201610819
  25. Surface modification of lipid-based nanocarriers for cancer cell-specific drug targeting vol.47, pp.3, 2017, https://doi.org/10.1007/s40005-017-0329-5
  26. From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers vol.56, pp.24, 2017, https://doi.org/10.1002/anie.201610819
  27. RGD-mediated delivery of small-molecule drugs vol.9, pp.6, 2017, https://doi.org/10.4155/fmc-2017-0008
  28. Water-soluble and amphiphilic phospholipid copolymers having 2-methacryloyloxyethyl phosphorylcholine units for the solubilization of bioactive compounds pp.1568-5624, 2017, https://doi.org/10.1080/09205063.2017.1377023
  29. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies pp.1573-0646, 2017, https://doi.org/10.1007/s10637-017-0506-4
  30. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines pp.21922640, 2017, https://doi.org/10.1002/adhm.201700432
  31. Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine vol.9, pp.14, 2014, https://doi.org/10.2217/nnm.14.115
  32. Fluorescence Characterization of Gold Modified Liposomes with Antisense N-myc DNA Bound to the Magnetisable Particles with Encapsulated Anticancer Drugs (Doxorubicin, Ellipticine and Etoposide) vol.16, pp.3, 2016, https://doi.org/10.3390/s16030290
  33. Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application vol.19, pp.1, 2018, https://doi.org/10.3390/ijms19010263
  34. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response vol.19, pp.10, 2018, https://doi.org/10.3390/ijms19102922
  35. evaluation vol.8, pp.43, 2018, https://doi.org/10.1039/C8RA03607A
  36. Membrane Loaded Copper Oleate PEGylated Liposome Combined with Disulfiram for Improving Synergistic Antitumor Effect In Vivo vol.35, pp.7, 2018, https://doi.org/10.1007/s11095-018-2414-5
  37. Liposomal Drug Delivery Systems and Anticancer Drugs vol.23, pp.4, 2018, https://doi.org/10.3390/molecules23040907